Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07707375
PHASE1

A Study of LY4268989 (MORF 057) in Healthy Participants

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The purpose of this study is to identify if two different tablets of LY4268989 (MORF 057) work similarly in healthy participants given different meals. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. There will be 18 inpatient stays at the clinical research unit (CRU). The study will last about 9 weeks.

Official title: A Phase 1 Study to Investigate the Pharmacokinetics, Safety and Tolerability of LY4268989 (MORF-057) in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2026-07

Completion Date

2026-10

Last Updated

2026-07-16

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

LY4268989

Administered orally

Locations (1)

Fortrea Clinical Research Unit

Daytona Beach, Florida, United States